CytomX Therapeutics vs Pyxis Oncology
CTMX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTMX and PYXS compare
CytomX Therapeutics is the larger company, worth 3.4 times as much as Pyxis Oncology ($510M against $151M).
CytomX Therapeutics scores higher on the StockData Score (8 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTMX | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | $510M | $151M |
| Share price | $2.34 | $1.81 |
| Change, 1 year | −28.2% | −45.3% |
| Change, 5 years | −64.5% | −85.0% |
| Beta (5Y) | 1.60 | 1.62 |
| Employees | 69 | 56 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 27.9× | – |
| P/B | 1.7× (better) | 13.2× |
| FCF yield | −16.2% | – |
| Growth | ||
| Revenue growth (TTM) | −87.0% | – |
| Revenue growth, 5Y average | 2.2% | – |
| Net income growth (TTM) | −266% | – |
| EPS growth (TTM) | −179% | – |
| Profitability | ||
| Operating margin | −476% | – |
| Net margin | −435% | – |
| FCF margin | −451% | – |
| Return on equity | −37.8% (better) | −179% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 9.36 (better) | 1.34 |
| Altman Z-score | 1.45 (better) | −15.78 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −48.0% | – |
| Shareholder yield | −48.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 40.9% |
| Held by insiders | 1.5% | 20.4% |
| Insider net buying, 12 months | −$1.7M | −$107K (better) |
| Short interest, % of float | 19.0% | 7.4% |
Go deeper
- CTMX stock overview
- CTMX income statement
- CTMX valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.